García-Morúa A, Hernández-Torres A, Salazar-de-Hoyos JL, Jaime-Dávila R, Gómez- Guerra LS

Language: Spanish
References: 11
Page: 45-48
PDF size: 350.31 Kb.

ABSTRACT

Introduction: Urinary tract infections are the most common bacterial infections worldwide. Their etiology is predictable since E. coli is the principal pathogen (80-90%) and trimethoprim/sulfamethoxazole (TMP/SMX), ciprofloxacin, cephalosporins, nitrofurantoin and phosphomycin are the antibiotics most frequently used against this bacteria.
Materials and methods: Urine cultures reporting urinary tract infection made from December 2007 to January 2008 were reviewed.
Results: A total of 291 urine cultures were analyzed. The most frequent pathogen was E. coli (24.7%). Antibiotic sensitivity was 26% to ciprofloxacin, 85% to amikacin and 80% to nitrofurantoin.
Discussion: Empirical antibiotic therapy is necessary for treating community-acquired urinary tract infection. Age, sex, associated disease; infectious agent and infection location are all factors that are taken into consideration. TMP/SMX continues to be the first-line antibiotic administered, unless a bacterial resistance index above 20% is shown.
Conclusion: Due to the high bacterial resistance to what we regard as first-line antibiotics in empirical management, alternatives with common antibiotics such as nitrofurantoin and phosphomycin should be considered.

REFERENCES

1. Arslan H, Azap OK, Onder Ergönül O, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005:56;914-918.

2. Drekonja DM, Johnson JR. Urinary tract infections. Prim Care. 2008: 35; 345-367.

3. Mohammed Akram, Mohammed Shahid, Asad U Khan. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. Ann Clin Micro Antimic 2007: 6(4); 1-7.

4. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008:8; 159-166.

5. Cohen AE, Lautenbach E, Morales KH, Linkin DR. Fluoroquinoloneresistant Escherichia coli in the long-term care setting. Am J Med 2006:119:958-963.

6. Goldstein FW. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France: Multicentre study group. Eur J Clin Biol Infect Dis. 2000:19; 112-117.

7. Sanche Merino JM, Guillan M Cristina, Fuester F Carlos, Lopez M Ramiro, González P Martha, Raya F Carmen, García A Jesús. Evolución de la resistencia a antibióticos de E coli en muestras de orina procedentes de la comunidad. Arch Esp Urol 2008: 61(7):776-780.

8. Ena Javier, Arjona Francisco, Martínez Carmen, López Ma. del Mar, Amador Concepción. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing E coli. Urology 2006:68; 1169-1174.

9. Gagliotti C, Buttazzi R, Sforza S, Moro ML; Emilia-Romagna Antibiotic Resistance Study Group. Resistance of fluoroquinolones and treatment failure/shirt-term relapse of community-acquired urinary tract infections caused by Escherichia coli. J Infect 2008 Aug 14 (Epub).

10. Al-hassan MN, Wilson JW, Lahr BD, Eckel-Passow JE, Baddour L. Incidence of Pseudomonas aeruginosa Bacteria: A Population-Based Study. Am J Med 2008:121; 702-708.

11. Kashanian J, Hakimian P, Blute M Jr, Wong J, Khanna H, Wise G, Shabsigh R. “Nitrofurantoin: The return of an old friend in the wake of growing resistance” BJU Int 2008;102(11):1634-7.